Cohort · P3-PDA-C1432Active studySynthetic mock data
Arm B — standard-of-care
Owner AW · last updated 2026-04-21
Size
124
Status
locked
Inclusion criteria
3
Exclusion criteria
2
Definition
Inclusion
- +Confirmed PDA on histology
- +ECOG 0-1
- +Randomized to standard-of-care arm
Exclusion
- −Prior systemic therapy < 12 months
- −Hepatic insufficiency (Child-Pugh B/C)
lockedP3-PDA-C1432Owner AWLast updated 2026-04-21
Enrollment over time
From wk 0 (n=0) to wk 28 (n=124)
Subjects in cohort (12)
| Subject | MRN | Age / Sex | Site | Enrolled | Status |
|---|---|---|---|---|---|
| PDA-B-001 Maria Alvarez | MRN 6024200 | 48 / F | Site 03 — Chicago | 2025-08-12 | withdrawn |
| PDA-B-002 Henry Müller | MRN 6024201 | 51 / M | Site 09 — Munich | 2025-08-17 | active |
| PDA-B-003 Rachel Sørensen | MRN 6024202 | 54 / F | Site 12 — Singapore | 2025-08-22 | active |
| PDA-B-004 Robert Adebayo | MRN 6024203 | 57 / M | Site 14 — Boston | 2025-08-27 | active |
| PDA-B-005 Priya Iversen | MRN 6024204 | 60 / F | Site 18 — Toronto | 2025-09-01 | active |
| PDA-B-006 Theo O'Connor | MRN 6024205 | 63 / M | Site 22 — Madrid | 2025-09-06 | active |
| PDA-B-007 Sara Tanaka | MRN 6024206 | 66 / F | Site 03 — Chicago | 2025-09-11 | active |
| PDA-B-008 Antonio Marquez | MRN 6024207 | 69 / M | Site 09 — Munich | 2025-09-16 | active |
| PDA-B-009 Aisha Hassan | MRN 6024208 | 72 / F | Site 12 — Singapore | 2025-09-21 | active |
| PDA-B-010 Omar Singh | MRN 6024209 | 75 / M | Site 14 — Boston | 2025-09-26 | active |
| PDA-B-011 Fatima Patel | MRN 6024210 | 48 / F | Site 18 — Toronto | 2025-10-01 | active |
| PDA-B-012 David Garcia | MRN 6024211 | 51 / M | Site 22 — Madrid | 2025-10-06 | completed |
Linked study
P3-PDA-C1432
RECIST-style longitudinal research workspace
Progression-free survival at 32 weeks · 314/380 enrolled
Sister cohorts in P3-PDA-C1432
Endpoints attached to this protocol
Cross-links